Ramipril

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis

Trial Timeline

Oct 1, 2003 → —

NCT ID

NCT01053910

About Ramipril

Ramipril is a approved stage product being developed by Sanofi for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01053910. Target conditions include Atherosclerosis.

What happened to similar drugs?

8 of 20 similar drugs in Atherosclerosis were approved

Approved (8) Terminated (4) Active (10)

🔄Orforglipron + PlaceboEli LillyPhase 3

🔄Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3

🔄Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3

✅Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved

✅Rosuvastatin + PlaceboAstraZenecaApproved

🔄Rosuvastatin + AtorvastatinAstraZenecaPhase 3

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00437463	Phase 3	Completed	Jul 1, 2004	Sep 1, 2010	Glomerulonephritis
NCT00273533	Phase 2/3	Completed	Jun 1, 2004	Jul 1, 2006	Arthritis, Rheumatoid
NCT00268619	Phase 3	Completed	Jun 1, 2004	—	Myocardial Ischemia
NCT01053910	Approved	Completed	Oct 1, 2003	—	Atherosclerosis
NCT00325806	Approved	Completed	May 1, 2000	Aug 1, 2005	Hypertension

Competing Products

20 competing products in Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Olmesartan medoxomil + Placebo	Daiichi Sankyo	Phase 3	40
Pactimibe sulfate	Daiichi Sankyo	Phase 2/3	30
Pactimibe	Daiichi Sankyo	Phase 2	35
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Phase 3	47
Micronized 17B-estradiol	Johnson & Johnson	Phase 2/3	38
Rosuvastatin + placebo + aspirin + placebo	AstraZeneca	Approved	43
Rosuvastatin + Placebo	AstraZeneca	Approved	35
rosuvastatin + placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Vorapaxar + Placebo	Merck	Phase 3	40
Vorapaxar + Placebo + Aspirin + Clopidogrel	Merck	Phase 2	35
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
lovastatin	Merck	Phase 2/3	38
Ezetimibe + Placebo	Merck	Approved	43
Vorapaxar + Placebo	Merck	Phase 3	32
Niaspan	Merck	Pre-clinical	22